Gilead entered the inflammation space more deeply by paying $1.28 billion upfront to PepStar Therapeutics for a Phase 1 oral IL-23 program, according to the companies’ deal terms. The transaction highlights continued partner appetite for early immunology assets that can be delivered orally. The arrangement gives Gilead access to an IL-23 targeting strategy aimed at inflammatory disease, with the near-term value tied to the program’s Phase 1 clinical progress. For PepStar, the funding supports development of its pipeline while preserving optionality for later combinations or licensing. The deal adds another large, upfront-backed expansion by a major biotech into inflammation—an area where competitive differentiation often depends on dosing convenience, safety, and biomarker strategy.